Company news
Mustang Bio, Inc. (NASDAQ:MBIO) news
Mustang Bio, Inc. news releases on 6ix. Latest, Jul 7, 2025: Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells)…
Press releases & updates
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-101 (IL13Ra2-targeted CAR T-cells) to Treat Astrocytomas and Glioblastoma
July 7, 2025
Mustang Bio Regains Compliance with Nasdaq Capital Market Requirement
March 5, 2025
Mustang Bio Announces Sale of Fixed Assets and Exit of Facility
February 27, 2025
Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
February 10, 2025
Mustang Bio Announces Closing of $8 Million Public Offering
February 9, 2025
Mustang Bio Announces Pricing of $8 Million Public Offering
February 5, 2025
Mustang Bio Announces Reverse Stock Split
January 13, 2025
Mustang Bio Receives Positive Listing Determination from Nasdaq
November 11, 2024
Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma
November 6, 2024
Mustang Bio : Announces Exercise of Warrants for $4 Million Gross Proceeds Form 8 K
October 23, 2024
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds
October 23, 2024
Mustang Bio Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
June 19, 2024
Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of phase Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy
June 18, 2024
Mustang Bio Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR-T Therapy
June 16, 2024
Mustang Bio Announces Closing of $4 Million Public Offering
May 1, 2024
Mustang Bio Announces Pricing of $4 Million Public Offering
April 28, 2024
Mustang Bio : Costs Associated with Exit/Disposal - Form 8-K
April 12, 2024
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
March 27, 2024
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
March 10, 2024
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
March 6, 2024
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
January 10, 2024
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting
December 10, 2023
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
November 13, 2023
Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting
November 1, 2023
Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
October 29, 2023
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
October 25, 2023
Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
October 25, 2023
Mustang Bio to Participate in Upcoming September 2023 Investor Conferences
September 6, 2023
Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy
August 15, 2023
Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
August 13, 2023
Mustang Bio to Participate in Two August 2023 Investor Conferences
August 2, 2023
Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences
July 30, 2023
Mustang Bio Announces Participation in Upcoming Scientific Meetings
July 5, 2023
Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
June 14, 2023
Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
June 11, 2023
Mustang Bio Announces Strategic Manufacturing Partnership and Portfolio Updates
May 17, 2023
Mustang Bio Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
May 11, 2023
Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy
May 10, 2023
Mustang Bio Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
March 28, 2023
Mustang Bio to Participate in Cantor’s The Future of Oncology Virtual Symposium
March 27, 2023
Mustang Bio to Participate in the B. Riley Securities’ 3rd Annual Oncology Conference
January 16, 2023
Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones
December 18, 2022
Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
November 13, 2022
Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia
October 26, 2022
Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
October 5, 2022
Mustang Bio to Participate in Upcoming September 2022 Investor Conferences
September 7, 2022
Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
August 10, 2022
Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency
July 26, 2022
Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia
June 21, 2022
Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy
June 12, 2022